NCT00000492

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Sep 1, 1977
Primary completion: —
Completion date: Oct 1, 1981
First posted: —
Last posted: —
Enrollment: —
Arms / groups: — / —
Source: AACT · pre-existing

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
University of California, DavisOfficial
Rhode Island HospitalOfficial
University of NebraskaOfficial
University of South CarolinaOfficial
Atlantic Health SystemOfficial
Northwestern UniversityOfficial
University of Southern CaliforniaOfficial
State University of New YorkOfficial
Geisinger ClinicOfficial
Maimonides Medical CenterOfficial
Emory UniversityOfficial
Boston UniversityOfficial
University of MontrealOfficial
Salt Lake Clinic Research FoundationOfficial
Miami Heart InstituteOfficial
Lankenau HospitalOfficial
Bio-Science LaboratoriesOfficial
Pacific Health Research InstituteOfficial
Anthropometrics Heart ClinicOfficial
Greater Baltimore Medical CenterOfficial
Medical College of VirginiaOfficial
Dartmouth UniversityOfficial
Rutgers UniversityOfficial
Rush UniversityOfficial
University of RochesterOfficial
University of California, BerkeleyOfficial
Northwell HealthOfficial
Baylor UniversityOfficial
University of MinnesotaOfficial
Department of Veteran AffairsOfficial
Henry Ford Health SystemOfficial
Kaiser FoundationOfficial
Icahn School of Medicine at Mount SinaiOfficial

Drugs studied

propranolol

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.